

## Global Pharyngitis Market to Projected to Grow to US\$ 2.08 Billion by 2034, Reports Fact.MR

Growing traction for novel therapeutics set to drive demand for pharyngitis treatment solutions, asserts Fact.MR in its recently updated market study.

ROCKVILLE PIKE SUITE, MD, USA, August 7, 2024 /EINPresswire.com/ -- Increasing awareness related to the rising cases of viral infections among people is complementing global pharyngitis market growth, which is estimated to reach US\$ 1.45 billion in 2024. As per the updated research



study by Fat.MR, the market is forecasted to climb to a value of US\$ 2.08 billion by the end of 2034.

In recent years, there has been an increase in the cases of pharyngitis around the world, which is generating demand for related treatment products. Several clinical trials are being conducted to identify the more suitable formulation effective to treat sore throat, which is estimated to widen opportunities for market players. Growing focus on patients receiving medication according to clinical requirements and their individual needs is forecasted to work as one of the prominent market growth drivers. Moreover, growing R&D activities for the development of more effective antibiotics with minimal side effects are set to widen opportunities for market players.

For More Insights into the Market, Request a Sample of this Report: <a href="https://www.factmr.com/connectus/sample?flag=S&rep\_id=361">https://www.factmr.com/connectus/sample?flag=S&rep\_id=361</a>

Key Takeaway from Market Study

Worldwide demand for pharyngitis treatment is estimated at US\$ 1.45 billion in 2024.

The global pharyngitis market is forecasted to reach US\$ 2.08 billion by the end of 2034.

The market has been projected to advance at a CAGR of 3.7% from 2024 to 2034.

North America is expected to account for 35.9% share of global market revenue by the end of 2034.

Demand for pharyngitis treatment solutions in South Korea is calculated to increase at 4.4% CAGR from 2024 to 2034.

Retail pharmacies & drug stores are approximated to account for 58.5% share of global sales of pharyngitis treatment products.

"Growing incidence of pharyngitis, increasing awareness related to viral infections, and rising demand for antiviral drugs are set to contribute to market growth," says a Fact.MR analyst.

Oral Drug Delivery Mode Gaining Prominence among Healthcare Providers and Patients

Worldwide demand for pharyngitis treatment products offered through oral mode is projected to increase at a CAGR of 3.6% and reach a value of US\$ 879.7 billion by the end of 2034. This drug administration route is preferred due to its high patient compliance and convenience. In addition, the cost-effectiveness of pharyngitis treatment products consumed through oral delivery mode is also driving their demand across regions.

Get Customization on this Report for Specific Research Solutions: <a href="https://www.factmr.com/connectus/sample?flag=S&rep\_id=361">https://www.factmr.com/connectus/sample?flag=S&rep\_id=361</a>

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the pharyngitis market, presenting historical demand data (2018 to 2023) and forecast statistics for the period (2024 to 2034).

The study divulges essential insights into the market based on drug class (beta lactams, macrolides, cephalosporins, fluoroquinolones, tetracycline), mode of delivery (oral, intravenous, intramuscular), and distribution channel (hospital pharmacies, retail pharmacies & drug stores, online pharmacies), across six major regions of the world (North America, Europe, East Asia, Latin America, South Asia & Oceania, and MEA).

Key Market Players -

Pfizer Inc. | Novartis AG | GlaxoSmithKline PLC | Zambon Group SpA | BioStar Pharmaceuticals Inc.

Checkout More Related Studies Published by Fact.MR Research:

<u>Amoxicillin Drugs Market</u> By Infection Type (Skin Infections, ENT (Ear, Nose & Throat) Infections, Stomach Infections), By Route of Administration (Oral, Intravenous), By Form (Tablets, Capsule, Suspensions), By Distribution Channels - Global Market Insights 2018 to 2028

Revenue in the global <u>parenteral drug market</u>, according to an updated Fact.MR report, is projected to reach US\$ 595.63 billion in 2024. Worldwide sales of parenteral drugs have been forecasted to rise at a CAGR of 5.5% and climb to US\$ 1,020.17 billion by 2034-end.

## About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.

Contact: 

11140 Rockville Pike 
Suite 400 
Rockville, MD 20852 
United States

Tel: +1 (628) 251-1583

Sales Team: Dales@factmr.com Dales Team: D

Follow Us: \( \text{LinkedIn} \( \text{| \text{| Twitter} \( \text{| \text{| Blog} \text{| }} \)

S. N. Jha Fact.MR +1 628-251-1583 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/733739232

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.